Publications

  1. Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA, McGree ME, Weaver AL, Dowdy SC. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol. 2014 Aug; 124(2 Pt 1):307-15.
    View PubMed
  2. Casey PM, Gallenberg MM, Kastner TM, Barrette BA, Chantigian PD, Shuster LT, MacLaughlin KL, Allensworth SK, Weaver AL. Outcomes in women age 40 years and older with cytologically benign endometrial cells. Am J Obstet Gynecol. 2012 Nov; 207(5):379.e1-6. Epub 2012 Aug 16.
    View PubMed
  3. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45(3):490-7. Epub 2009 Aug 03.
    View PubMed
  4. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1; 70(3):875-82. Epub 2010 Jan 26.
    View PubMed
  5. Hartmann L, Cliby W, Long H, Peethambaram P, Barrette B. Phase I trial of intraperitoneal administration of an engineered attenuated strain of measles virus, genetically modified to express carcinoembryonic antigen (CEA) in patients with recurrent ovarian cancer. [forthcoming] J Clin Oncol. 2009; JCO/2407.
  6. Clavero JM, Deschamps C, Cassivi SD, Allen MS, Nichols FC 3rd, Barrette BA, Larson DR, Pairolero PC. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006 Jun; 81(6):2004-7.
    View PubMed
  7. Yawn BP, Barrette BA, Wollan PC. Ovarian cancer: The neglected diagnosis. Mayo Clin Proc. 2004 Oct; 79(10):1277-82.
    View PubMed
  8. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002; 107:247-58.
    View PubMed
  9. Yawn BP, Wollan P, Klee M, Barrette B. Ovarian carcinoma: care and survival in a community-based population. Clin Ther. 2001 Jan; 23(1):146-59.
    View PubMed
  10. Barrette BA, Srivatsa PJ, Cliby WA, Keeney GL, Suman VJ, Podratz KC, Roche PC. Overexpression of p34cdc2 protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997 Oct; 72(10):925-9.
    View PubMed
  11. Barrette B, Srivatsa P, Cliby W, Keeney G, Suman V, Podratz K, Roche P Over-expression of p34(cdc2) protein kinase in epithelial ovarian carcinoma. Mayo Clin Proc. 1997; 72(10):925-929.
    View PubMed
  12. Barrette B. Abnormal pap smears: Bethesda classification, treatment guidelines. Mayo Clinic Ob/Gyn Clinical Reviews. 1993 Nov 11-12.
  13. Lambert B, Barrette B, LePage Y. Studies of DNA content in cervical intraepithelial neoplasia by cytologic and histologic flow cytometry. Can J Surg. 1989 May; 32(3):204-6.
    View PubMed
  14. Lambert B, Latreille J, Barrette B. DNA content in CIN: a prognostic tool. Colposcopist. 1986; 18.